FDA-approved antivirals ledipasvir and daclatasvir downregulate the Src-EPHA2-Akt oncogenic pathway in colorectal and triple-negative breast cancer cells.-论文-万方医学网

作者： Betlem,Mezquita ^[1] ; Marjorie,Reyes-Farias ^[2] ; Miquel,Pons ^[3]

作者单位： Departament de Ciències Bàsiques, Universitat Internacional de Catalunya (UIC), Josep Trueta s/n, Sant Cugat del Vallès, 08195, Spain. ^[1] Biomolecular NMR laboratory. Department of Inorganic and Organic Chemistry. Universitat de Barcelona (UB), Baldiri Reixac, 10-12, Barcelona 08028, Spain. ^[2] Biomolecular NMR laboratory. Department of Inorganic and Organic Chemistry. Universitat de Barcelona (UB), Baldiri Reixac, 10-12, Barcelona 08028, Spain. Electronic address: mpons@ub.edu. ^[3]

主题词人类(Humans);苯咪唑类(Benzimidazoles);动物(Animals);吡咯烷类(Pyrrolidines);咪唑类(Imidazoles);小鼠(Mice);原癌基因蛋白质c-akt(Proto-Oncogene Proteins c-akt);src族激酶类(src-Family Kinases);芴类(Fluorenes);细胞系, 肿瘤(Cell Line, Tumor);抗病毒药(Antiviral Agents);氨甲酸酯类(Carbamates);减量调节(Down-Regulation);缬氨酸(Valine);结直肠肿瘤(Colorectal Neoplasms);信号传导(Signal Transduction);NIH 3T3细胞(NIH 3T3 Cells);女(雌)性(Female);细胞增殖(Cell Proliferation);美国食品和药物管理局(United States Food and Drug Administration);药物批准(Drug Approval);美国(United States)

DOI 10.1016/j.biopha.2024.117325

PMID 39226729

发布时间 2024-09-25

检索历史清除

FDA-approved antivirals ledipasvir and daclatasvir downregulate the Src-EPHA2-Akt oncogenic pathway in colorectal and triple-negative breast cancer cells.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

相似文献

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

FDA-approved antivirals ledipasvir and daclatasvir downregulate the Src-EPHA2-Akt oncogenic pathway in colorectal and triple-negative breast cancer cells.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

相似文献

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

相关期刊

检索历史清除